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Abstract 
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pi-
tuitary gland and multiple cell types, including macrophages (Mø), dendritic cells (DC) and 
T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such 
as TNF-, nitric oxide and cyclooxygenase 2 (COX-2). These important MIF characteristics 
have prompted investigators to study its role in parasite infections. Several reports have 
demonstrated that MIF plays either a protective or deleterious role in the immune response 
to different pathogens. Here, we review the role of MIF in the host defense response to some 
important protozoan infections. 
Key words: Macrophage migration inhibitory factor; Protozoan infections; Inflammatory response; 
Control of parasite infections; innate immune response. 
Introduction 
MIF  was  originally  discovered  (in  1966)  as  a 
lymphokine, derived from activated T-cells, that in-
hibited the random migration of macrophages in vitro 
and was shown to be involved in the mechanism of 
delayed-type  hypersensitivity  [1,  2].  Currently,  it  is 
known that MIF is a widely expressed and pleiotropic 
cytokine that functions as a critical upstream mediator 
of innate immunity and promotes numerous patho-
physiological processes [3-11], such as glomerulone-
phritis  [12,  13],  arthritis  [5,  14],  experimental  auto-
inmune  encephalomyelitis  (EAE)  [15],  experimental 
autoinmune  myocarditis  (EAM)  [16],  gram-negative 
[17-23] and gram-positive sepsis [23, 24], colitis [10, 
25], asthma [8] diabetes, and pancreatitis [26-28]. MIF 
is produced and secreted primarily by immune cells, 
such as lymphocytes, Mø, DC, neutrophils and pitui-
tary cells [29, 30]. MIF secretion is tightly regulated by 
stress  and  immune  stimuli,  including  endotoxins, 
inflammatory  cytokines  (interferon  (IFN)-γ,  tumor 
necrosis  factor  (TNF)-α)  and  glucocorticoids  [29, 
31-33]. Once secreted, MIF exhibits a broad range of 
immune  and  inflammatory  activities,  including  the 
induction of inflammatory cytokines such as TNF-α, 
IFN-γ,  interleukin  (IL)-1β,  IL-12,  IL-6  and,  CXCL8 
(also  known  as  IL-8),  among  others  [20,  32,  34-40]. 
MIF favors the expression of the Toll-like receptor 4 
(TLR4)  gene,  which  encodes  the  signal-transducing 
element  of  the  lipopolysaccharide  (LPS)  receptor 
complex  [24,  41, 42]  through  the  activation  of  tran-
scription factors of the ETS family [43]. In addition, 
MIF counter-regulates the immunosuppressive effects 
of glucocorticoids [32, 44-46], and it sustains macro-
phage  proinflammatory  functions  by  inhibiting  p53 
[47].  MIF  also  promotes  the  migration  and  recruit-
ment  of  immune  cells  inducing  the  expression  of 
chemokines  (monocyte  chemoattractant  protein 
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(MCP)-1, and adhesion molecules as intercellular ad-
hesion molecule (I-CAM)-1 and vascular cell adhesion 
molecule (V-CAM)-1 [48-51].  
Parasitic infections are important cause of mor-
bidity and mortality in humans, and the innate and 
adaptive  immune  responses  triggered  by  these  or-
ganisms  are  critical  in  determining  their  outcome. 
Parasitic-associated factors and host-derived compo-
nents  are  also  important  inflammatory  modulators. 
Recognition  of  these  molecules  triggers  signaling 
pathways that influence the host-response to infection 
and  disease  progression.  In  this  context,  MIF  is 
over-expressed in most parasitic infections; however, 
the role of MIF in the immune response to parasitic 
infections has only recently been elucidated, provid-
ing valuable information that must to be clarified. The 
aim of this review is to provide an overview of the 
current  literature  regarding  the  role  of  MIF  in  im-
portant  protozoan  infections.  We  will  focus  on  im-
mune response modulation, the implications of such 
modulation  and  the  possible  mechanisms  involved. 
We will also discuss the differences and similarities in 
MIF activity infections caused by distinct parasites. 
Malaria  
Malaria is caused by intracellular parasitic pro-
tozoa of the genus Plasmodium (P) and is transmitted 
by  the  infected  female  Anopheles  mosquito  during 
blood meals. Malaria is a major cause of severe illness 
and death in many part of the world. It causes 300 to 
500 million new infections per year resulting in ap-
proximately 1 to 2 million deaths, and these primarily 
occur  in  children  under  the  age  of  5  years.  Severe 
anemia and cerebral malaria are the major complica-
tions leading to malaria-induced morbidity and mor-
tality [52]. Factors such as host genetic variation, age 
of first exposure, rate of exposure (endemicity) [53, 54] 
and the  host immune response to  P. falciparum [55] 
play an important role in the generation of symptoms 
and disease [56, 57]. 
Remarkable research on the role of MIF in ma-
laria has been recently conducted (Table 1).  
 
Table 1. MIF in Malaria infection 
Parasite  Model  Disease   in vitro/ 
in vivo 
Treatment   Properties   MIF role     Ref.  
P. chabaudi   BALB/c 
mice 
SMA  in vitro  rMIF+ Epo  ↓BFU-E 
↓CFU-GEMM↑ 
Parasitemia 
Causes erythropoiesis suppres-
sion and SMA development 
[58] 
          in vivo      ↑MIF ↑SMA       
   BALB/c 
mice  
SMA  in vitro  rMIF+IFN-γ; 
TNF-α+Epo 
↓BFU-E 
↓CFU-E 
↑ERK1/2 
↓P38 
Supressed erythropoietin colony 
formation and sinergized with 
TNF-α and IFN-γ modulating 
MAPK activation. 
[60] 
  MIF-KO 
BALB/c 
mice  
SMA   in vivo    ↑Parasitemia  
↓Mortality 
↑ BFU-E 
↑ CFU-E 
    
P. chabaudi 
adami556-KA 
 
 
MIF-KO 
BALB/c 
mice  
Malaria  In vivo    ↓Parasite burden 
↓cumulative parasitemia 
↓Peak parasitemia at day 4 
post-infeccion 
MIF modulates the balance 
between Th1 and Th2 effector 
responses, by attenuating the 
development of Th1 responses, 
inducing anti-inflammatory 
cytokines during the infection of 
P. c. adami. 
[59] 
      In vitro  Anti-MIF  ↓ parasitemia 
↓Peak parasitemia at day 4 
post-infeccion in WT mice 
   
  MIF KO 
 
     
 
 CD4+T cells showed ↑IFNγ, 
↓IL-10 at day 4 p.i. 
↑ IL-4 (presumable mast cells or 
eosiniphils) 
   
P. vivax  Adults Ad-
olescents 
Children 
Acute  
malaria 
uncompli-
cated 
in vivo    ↑MIF, TNF-α, IFN-γ, IL-12, 
MCP-1 and IL-10 
↑IgM ↓Hb and ↑MIF 
Enhancing the Ab production 
against the parasite which cause 
erythrocyte lysis 
[62] 
P. falciparum  Zambean 
children 
Malaria  in vivo    ↑MIF peripheral blood  Promote polymorphisms, mod-
ulate the immune response to 
hemozoin  
[60] 
        in vitro   Hemozoin  ↓MIF from Mo with 5-CATT 
(low repeat) 
↑MIF from Mo 6/7 CATT 
   
   Pregnant 
woman 
Placental 
malaria 
in vivo    ↑MIF in IVB 
↓MIF in peripheral and cord 
Enhancing the local immune 
response 
[63] Int. J. Biol. Sci. 2011, 7 
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plasma 
         in vivo    ↑MIF in placental plasma ↓IL-12 
IL-18 TGF-β1 
Enhancing immune response  [64] 
        in vitro    ↓MIF in PBMC 
↑MIF in IVB cells 
   
           in vivo     ↑MIF in amniotic ephitelium 
and IVBMC 
↓MIF in villous stroma and 
extravillous trophoblast 
  [65] 
   Indian 
adults 
Cerebral 
malaria  
in vivo     ↑Plasma MIF in non-survivors 
↓Plasma MIF in patients with 
mild malaria 
Protective role in CM and in-
duce fatal complications 
[61] 
  Adults Ad-
olescents 
Children
    
Acute infec. 
malaria 
un-complic
ated  
in vivo     ↑MIF, TNF-α, IFN-γ and MCP-1 
in peripheral blood ↑IgM and 
IgG against parasite correlated 
to ↓Hb conc.  
Enhancing the Ab against para-
site which may cause erythro-
cyte lysis 
[62] 
  Malawian 
Children 
Cerebral 
malaria 
in vivo    ↓MIF in cerebral vascular walls 
skeletal muscle and chest 
Absence of MIF have a survival 
advantage in preventing intra-
cranial hemorrhage in systemic 
infections 
[66] 
   Gabonese 
children 
Acute ma-
laria 
in vivo    ↓MIF in peripheral blood PGE2 
and TGF-β1 ↑parasitemia 
 ↑IFN-γ, TNF-α, iNOS and IL-10  
Reduced MIF and TGF-β1 pro-
mote an ineffective immune 
response that enhanced patho-
genesis 
[67] 
      in vitro    ↓MIF mRNA in PBMC     
   Kenyan 
children 
SMA   in vivo      ↓MIF in plasma 
↓MIF mRNA in PBL ↑% PCM 
related to ↑SMA and ↓MIF in 
PBMC 
A protective response against 
severe disease 
[68] 
         in vitro   pfHz or sHz  ↓MIF in PBMC     
   Caucasian 
Adults  
Acute ma-
laria 
in vivo    ↓Plasma MIF 
↓Peripheral lymphocytes 
↑Parasitemia 
 Hb unchanged 
Reallocation of lymphocytes to 
tissues during acute malaria 
explains the decline in circulat-
ing lymphocytes that may 
causes MIF↓ in plasma 
[69] 
   Zambian 
children 
malaria  in vivo    ↑6,7 and 8 CATT repeats at MIF 
-794 allele are correlated to 
↑Parasitemia ↑5 CATT repeat at 
MIF-794 allele is correlated to 
↓Parasitemia 
Protective effect of MIF -794, 5 
CATT allele 
[81] 
   Kenyan 
children 
Acute ma-
laria 
in vivo     ↑risk of developing HDP of C/C 
compared to G/G genotype 
MIF -173 G/C C/C genotypes 
are associated with an increased 
risk of HDP, ↓plasma MIF but 
not increased SMA susceptibil-
ity 
[82] 
       in vitro   pfHz    ↑MIF in PBMC with MIF -173 
G/G genotype compared to 
G/C genotype 
   
   Kenyan 
children 
SMA  in vivo    ↑longer (7, 8) CATT repeats at 
MIF -794 alleles associated to 
↑SMA and ↓MIF compared to 5, 
6 CATT repeats 
7C and 8C haplotypes related to 
↑SMA 
↓MIF compared to 6 G haplo-
type 
MIF promoter at the -173 and 
-794 polymorphisms can both 
confer protection or susceptibil-
ity to SMA. 
Carriers of the disease associat-
ed alleles have decreased pe-
ripheral blood MIF 
[83] 
Erythroid (BFU-E), multipotential (CFU-GEMM), and granulocyte-macrophage (CFU-GM) progenitor-derived colony formation. ery-
tropoyetin (Epo); Monocytes (Mo); Intervillous blood (IVB); Peripheral bone marrow cell (PBMC); Peripheral blood lymphocytes (PBL); 
Pigment containing monocytes (PCM); Mononuclear intrvillous cells (IVBMC); Hingh density parasitemia (HDP); P. falciparum hemozoin 
(pfHz); Sintetic Hemozoin (sHz); Severe Malaria Anemia (SMA); Cerebral malaria (CM). 
 
 
In  one  study,  Martiney  et al.  reported  that  the 
ingestion of P. chabaudi-infected erythrocytes or ma-
larial  pigment  (hemozoin)  by  macrophages  induces 
the release of MIF, resulting in high circulating levels 
of  MIF  in  the  sera  and  bone  marrow  of  P. chabau-
di-infected BALB/c mice. Furthermore, recombinant 
MIF  administration  suppressed  the  erythroid  and 
other  myeloid  progenitor  development  in  the  pres-
ence  of  erythropoietin  an  erythropoiesis  inhibitory 
role for MIF [58]. These findings were supported later 
in vitro studies in which the combined subinhibitory 
concentrations of MIF, TNF-α and IFN-γ acted syner-
gistically to inhibit erythroid differentiation and he-
moglobin production by antagonizing the pattern of Int. J. Biol. Sci. 2011, 7 
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mitogen-activated protein (MAP) kinase phosphory-
lation that normally occurs during erythroid progen-
itor differentiation. An in vivo study, using P. chabau-
di-infected MIF knockout (KO) mice, showed that the 
absence of MIF is related to an increase in erythro-
poiesis  and  decreased  mortally.  Correlated  with  a 
recent study by Malu DT et al, where MIF KO mice 
showed increased resistance to  P. chabaudi adami in-
fection  associated  with  enhanced  IFN-γ  and  reduce 
IL-4 and IL-10 production by CD4+ T cells, suggesting 
a regulatory role for MIF on T cell activation, which 
favors  a  th2  type  susceptible  response  in  WT  mice 
[59].  In  addition,  increased  MIF  circulating  levels 
found in Zambian children supports the hypothesis 
that  Plasmodium  infection  is  a  potent  stimulus  for 
systemic MIF expression in humans, which  may be 
involved in the pathophysiology of malaria-induced 
anemia [60]. 
Recent research regarding the role of MIF in the 
pathogenesis  and  outcome  of  cerebral  malaria 
showed that patients with mild malaria and survivors 
of  cerebral  malaria  had  low  peripheral  blood  MIF 
levels  compared  to  cerebral  malaria  non-survivors, 
suggesting  that  elevated  MIF  levels  may  be  a  risk 
factor for mortality in cerebral malaria patients [61]. 
Moreover,  patients  with  P.  falciparum  and  P.  vivax 
infections  showed  significant  increases  in  MIF, 
TNF-α, IFN-γ, IL-12, IgM and MCP-1 in the peripheral 
blood.  Also  high  IgM  antibody  levels  against  stage 
parasite forms were associated with low hemoglobin 
(Hb)  and  increased  MIF  levels,  indicating  that  MIF 
participates in the inflammatory immune response to 
malaria. This response, in concert with other inflam-
matory cytokines and the production of specific an-
tibodies against the parasite, may lead to pathologic 
responses  [62].  However,  MIF  does  not  always  act 
systemically. Previous studies by Chaisavaneeyakorn 
et al reported significantly elevated MIF levels in the 
inter-villous blood (IVB) plasma in pregnant women 
with placental malaria compared to both peripheral 
plasma  and  cord  plasma  [63].  Similar  results  were 
obtained  by  Chaiyaroj  et  a.l,  who  observed  signifi-
cantly higher MIF production by inter-villous blood 
mononuclear cells (IVBMC) compared to peripheral 
blood mononuclear cells (PBMC), as well as high MIF 
levels  in  placental  plasma  compared  to  paired  pe-
ripheral plasma [64]. These data were confirmed by 
immunohistological  studies  in  term  placentas, 
demonstrating  that,  although  MIF  is  expressed  in 
various  cellular  compartments,  enhanced  MIF  ex-
pression occurs specifically in mononuclear cells and 
amniotic  epithelial  cells  in  placental  malaria  [65]. 
These data indicate that increased MIF levels in in-
fected  placentas  may  play  an  important  role  in  the 
local immune response, possibly through macrophage 
activation  for  parasite  clearance.  However,  not  all 
reports show local  or systemic MIF overexpression. 
Immunohistological  studies  have  reported  that,  alt-
hough MIF was found in the nuclei of skeletal muscle 
cells, it was not found in the cerebral vascular walls of 
cerebral  malaria  patients.  The  lack  of  MIF  overex-
pression in the cerebral vasculature may prevent ex-
cessive  cerebral  perfusion  pressure  and  the  risk  of 
intracranial  hemorrhage  during  systemic  inflamma-
tion. Interestingly, the role of MIF in nuclei has not yet 
been  determined  [66].  Moreover,  research  in  Gabo-
nese children with acute malaria has shown signifi-
cantly low MIF mRNA levels in PBMCs and low MIF 
protein levels in peripheral blood, which was associ-
ated with low levels of TGF-β1 in presence of TNF-α, 
IFN-γ,  and  inducible  nitric  oxide  synthase  (iNOS). 
These  results  suggest  that  the  reduction  of  trans-
forming  growth  factor  beta  (TGF)-β1  and  MIF  in 
children with acute malaria may promote an ineffec-
tive  immune  response  culminating  in  enhanced 
pathogenesis [67]. These findings are consistent with a 
later  study  in  357  Kenyan  children,  which  showed 
that  malaria-induced  anemia  was  associated  with 
decreased  circulating  MIF  levels.  The  authors  also 
showed  low  MIF  expression  in  peripheral  blood 
lymphocytes  (PBL),  peripheral  blood  mononuclear 
cells (PBMCs), and in a high percentage of pigment 
containing  monocytes  (PCM),  concluding  that  the 
effective production of MIF during childhood anemia 
may be protective against severe disease [68] (Fig 1). 
In  addition  a  recent  study  in  10  healthy  volunteers 
infected with P. falciparum, showed that a decrease in 
systemic MIF levels during acute infection is associ-
ated  with  a  decline  in  circulating  lymphocytes.  Be-
cause  T  cells  are  the  primary  source  of  circulating 
MIF, these results may be attributed to the realloca-
tion  of  lymphocytes  from  the  peripheral  plasma  to 
infected  tissues  leading  to  a  decrease  in  circulating 
MIF levels [69].  
Although much research has been conducted in 
humans, the role of MIF in malaria remains unclear 
partly due to genetic variability, as  malaria has ex-
erted selective pressure on the human genome [70]. 
Interestingly, some studies have attributed the varia-
tions  in  MIF  circulating  levels  and  susceptibility  to 
severe malaria-induced anemia to the tetranucleotide 
short tandem repeat polymorphism (STRP) MIF-794 
CATT and the single nucleotide polymorphism (SNP) 
MIF-173  G/C  allele  [8,  71-83].  The  -173  C  allele  is 
commonly  associated  with  elevated  MIF  expression 
and increased susceptibility to inflammatory diseases 
[71-75, 77, 78, 80], while longer CATT repeats (>5) at 
MIF-794  can  cause  increased  susceptibility  [80]  and Int. J. Biol. Sci. 2011, 7 
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irregular MIF production [74, 75, 79] in inflammatory 
diseases. Related to this, previous studies in Zambian 
children  have  shown  that  monocytes  with  longer 
CATT  repeats  (>5)  were  associated  with  high  MIF 
production [60]. Subsequent studies in Zambian and 
Kenyan children demonstrated that carriers of longer 
(>5) CATT repeats at the MIF -794 allele and the CC 
genotype at the MIF -173 allele, were associated with 
increased  susceptibility  to  high-density  parasitemia 
[81, 82]. Recently, Awandare et al., in a study in Ken-
yan  children,  reported  that  the  7C  and  8C 
MIF-794/-173 haplotypes and an increased number of 
CATT repeats (>5) in the MIF -794 allele were associ-
ated  with  increased  susceptibility  to  severe  malaria 
anemia  (SMA)  and  a  progressive  decrease  in  circu-
lating MIF concentrations. This group also discovered 
that the 6G haplotype and short CATT repeats were 
associated with decreased susceptibility to SMA and 
increased MIF production, suggesting that carriers of 
the  disease-associated  alleles  may  have  decreased 
MIF levels in the blood [83]. Moreover, even though 
these findings indicate a high prevalence of the short 
5/6, 7, and 8 CATT repeats at the -794 and -173 C al-
leles in Kenyan and Zambian children compared to 
Caucasians,  which  points  to  a  selective  pressure  in 
these  endemic  regions  by  P.  falciparum,  further  re-
search will be necessary to clarify the inconsistencies 
in previous studies regarding MIF circulating levels 
and to show the clear involvement of MIF in either 
malaria resistance or pathology (Fig 2). 
 
 
 
 
Figure 1. Overview about the role of MIF during Plasmodium infection. Theory 1. Mice infected with plasmodium (1) develop 
high MIF serum levels (2), MIF inhibits eritropoyesis (3) and promotes pathological complications increasing the risk of 
developing several malaria anemia (SMA) (4). Plasmodium infected human could develop low (3A) or high levels (3B) of MIF, 
depending of the (MIF´s polymorphisms expressed). Low levels of MIF correlates with high density parasitemia (HDP) in 
blood but low risk of developing SMA (5A). However, high expression of MIF induces SMA (5B). Plasmodium infected 
pregnant woman develop high levels of MIF in placental plasma, amniotic epithelium, mononuclear intervillous blood (IVB), 
and mononuclear tervillous cells (MIVC). All together indicate that MIF is associated to inhibition of eritropoyesis and 
promoting SMA, however it is not crucial in the control of the infection. 
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Figure 2. Overview about the role of MIF during Plasmodium infection. Theory 2. Human infected with plasmodium (1) down 
regulates the expression of MIF in peripheral lymphocytes (2), depending of the expressed MIF´s polymorphisms it may 
favors several malaria anemia (SMA) (B and C). In line with these observations high levels of MIF prevent SMA (A,D). All 
together indicate that MIF has a protective role against plasmodium infection and low levels of MIF increase the risk of 
developing SMA. 
 
Leishmaniasis  
Leishmaniasis is caused by protozoan parasites 
belonging to the genus Leishmania and approximately 
350 million men, women and children in 88 countries 
are in danger of contracting the disease. As many as 
12 million people may be currently infected, and an 
estimated 1–2 million new cases occur every year [84]. 
Generally, infection by these parasites can be divided 
into three main forms: cutaneous, mucocutaneous and 
visceral  leishmanioses.  The  disease  is  prevalent  in 
many tropical and subtropical regions of the world, 
where  it  is  transmitted  via  the  bite  of  an  infected 
sandfly [85]. 
Previous reports have shown that MIF plays a 
critical role mediating host resistance to Leishmania-
sis. Juttner et al. found in vitro that both recombinant 
murine or human MIF, at 1.5 and 2.5 μg/ml concen-
trations could activate macrophages to kill Leishmania 
major [86].  The  use  of  anti-TNF-α  antibody  or  TNF 
receptor p55-KO mice as well as L-NIL or iNOS-KO 
mice showed that leishmanicidal activity was medi-
ated by TNF-α autocrine signaling and the production 
of nitric oxide metabolites by macrophages after MIF 
stimulation. Moreover, both susceptible BALB/c and 
resistant C57BL/6 mouse strains expressed high lev-
els of MIF mRNA in lymph nodes draining the site of 
L.  major  infection.  Related  to  this,  in  a  study  by 
Satoskar  et  al.,  experimental  L.  major  infection  in 
C57BL/6 MIF KO and wild-type (WT) mice showed 
that MIF KO mice were more susceptible to disease 
due to significantly larger lesions and greater parasite 
burdens than WT mice. However, similar proliferative 
responses and production of IL-4 and IFN-γ cytokines 
by lymph nodes were observed when stimulated in 
vitro with L. major antigen (LmAg). In addition, IFN-γ 
stimulated  Mø  from  MIF  KO  mice  had  a  defective 
leishmanicidal  activity,  which  was  associated  with 
low superoxide and nitric oxide levels, and high IL-6 
levels. This finding suggests that susceptibility of MIF 
KO mice to L. major infection is due to an impaired 
macrophage  leishmanicidal  activity  rather  than  de-
regulation  of  Th1  and  Th2  responses  [87].  Further-
more, Xu et al. demonstrated that oral administration 
of attenuated Salmonella-transfected plasmids encod-
ing  the  murine  MIF  gene  and  the  TNF-α  gene  en-
hanced the resistance of BALB/c mice infected with L. 
major,  and this  resistance  was associated  with  high 
iNOS expression compared to other plasmids encod-
ing the MIF, TNF-α or IFN-γ genes alone. This indi-
cates that MIF may play an important role in the re-
sistance to leishmaniasis, likely by synergizing with 
other inflammatory cytokines, such as TNF-α via the 
induction  of  iNOS  expression  [88].  Interestingly, 
Kozaci et al. reveled that human patients with acute 
cutaneous leishmaniasis caused by L. tropica showed 
high  MIF  levels  compared  to  healthy  subjects  [89]. Int. J. Biol. Sci. 2011, 7 
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Moreover, a recent study by Santos-Oliveira J.R. et al. 
in  visceral  leishmaniasis  (VL)  patients,  the  authors 
demonstrated  that  high  LPS  levels  from  a  possible 
microbial  translocation  due  to  damage  by  visceral 
leishmaniasis  (VL)  was  correlated  with  increased 
pro-inflammatory cytokines (MIF, IFN-γ, TNF-α, IL-2, 
IL-6, IL-12, IL-17) and low numbers of CD4+ and CD8+ 
T cells, suggesting a strong lymphocyte activation by 
the  proinflammatory  cytokine  storm  that  lead  to 
lymphocyte  death  by  apoptosis,  therefore  MIF  may 
contribute in the inmuno-pathogenesis by LPS stim-
ulation during VL [90]. In addition, a clinical study by 
Bimal et al. reported that CD2+ T-cells isolated from 
patients with active visceral leishmaniasis (VL) pro-
duced high levels of MIF after anti-CD25 stimulation 
in vitro. Moreover, after anti-leishmanicidal treatment, 
patients  with  VL  showed  higher  numbers  of  CD2+ 
T-cells, indicating a possible role for CD2+ T cells and 
MIF in the immune response to VL [91]. Related to 
this, Kar, Metz, and McMahon-Pratt discovered that 
P-4  antigen-vaccinated  BALB/c  mice  presented 
without  lesions  or  detectable  parasites  after 
Leishmania  pifanoi  infection.  This  protection  was 
shown to be CD4+ T cell-dependent and lead to the 
production of MIF, TNF-α and IFN-γ, but not IL-4. 
Moreover,  the  addition  of  antibodies  against  either 
MIF, TNF-α or IFN-γ separately or simultaneously, to 
macrophages  from  P-4-immunized  mice  in  vitro, 
decreased  leishmanicidal  activity,  suggesting  that 
MIF potentially contributes to the control of L. pifanoi 
infection in P-4-vaccinated mice [92]. Together, these 
findings  demonstrate  a  crucial  role  for  MIF  in  the 
cellular immune response against leishmaniasis. MIF 
appears to be capable of killing Leishmania parasites 
by acting directly or indirectly with other cytokines, 
such as TNF-α and reactive products like nitric oxide. 
However,  additional  human  studies  are  needed  to 
confirm this data and, more importantly, to elucidate 
the  molecular  mechanisms  of  how  MIF  induces  its 
leishmanicidal activity. 
 
Table 2. MIF in Leishmaniosis 
Parasite  Model  Disease   in vitro/ 
in vivo 
Treatment   Properties   MIF role     Ref.  
L. major  BALB/c mice 
C57BL/6 mice 
CL  in vitro  rhMIF rmMIF, 
anti-TNF-  
↓Infected Mø 
↑ TNF-α by PECS 
↓amastigotes in Mø  
Induces a leishmanicidal 
activity in MO mediated 
by TNF-and NO  
[86] 
  TNF-KO 
p55-KO iNOs 
KO  
    TNF- KO
TNF-R55 KO 
(+ rMIF) 
L-NIL or iNOS 
KO+ MIF  
↓MIF   Mediate L. major killing in 
Mø 
 
        MIF + IFN-γ  ↑NO by Mø   Mediated leishmanicidal 
function 
 
        TGF-β, IL-13 
and IL-10 (+ 
rMIF) 
↓ MIF      
        Leishmania Ag 
or Con A 
↑MIF in lymph node cells     
      in vivo    ↑MIF mRNA in lymph 
nodes 
  [62][62] 
  C57BL/6 
MIF-KO mice 
CL  in vivo    ↑ Large lesions 
↑ parasites 
Induce in Møs leishmani-
cidal activity by 
up-regulating iNOS and 
NO 
[87] 
      in vitro  IFN-γ  ↓leishmanicidal activity 
↓NO and ↑IL-6 by Mø 
   
  BALB/c mice  CL  in vivo  Oral S. typhi-
murium trans-
fected with 
plasmid encod-
ing IFN-γ or 
MIF or TNF-α  
↓lesion size and parasites 
↑iNOS in spleen cells 
Therapeutic effect Syner-
gizes with TNF-α limiting 
the replication of Leish-
mania via NO synthesis. 
 
[88] 
L. tropica  Turkish pa-
tients 
CL  in vivo    ↑MIF in serum  Favors cellular immune 
response  
[89] 
Leishmania 
infantum 
chagasi 
Human  Viseral 
Leishmaniasis 
(VL) 
In vivo    ↑LPS levels in plasma cor-
related to ↑MIF, IL-6, ↑IL-8 
,↑IFABP levels, ↑sCD14, ↑% 
of TCD3 HLA-DR and ↑% of 
CD4+ CD25+ compared to 
Healthy Subjects (HS) 
↓CD4+ and CD8+ T cells but 
↑cellular activation. 
↑IFN-γ, TNF-α, IL-2, IL-6, 
MIF production may con-
tribute to the inflammato-
ry response in VL patients, 
and the increased suscep-
tibility to the 
inmunophatogenesis 
caused by LPS stimula-
tion. 
[90] Int. J. Biol. Sci. 2011, 7 
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IL-12, IL-17 and MIF) 
↑IL-4, IL-5, IL-13 and IL-10 
↑Chemokines (IL-8, MCP-1, 
MIP-1β) compared to HS. 
        Anti-Leishmania 
Therapy 
↓LPS in plasma, ↑CD4+ and 
CD8+ T cells, ↓sCD14, ↓MIF, 
↓IFABP levels and 
↓Pro-inflammatory cyto-
kines compared to active VL 
patients. 
   
L. donovani  Indian pa-
tients 
VL  in vivo    ↓TCD2+, active VL 
↑TCD2+, cured VL 
Important role for TCD2+ 
and MIF in immunity to 
VL 
[91] 
      in vitro  Anti-cd2   ↑ MIF, by T cells from active 
VL 
   
L. pifanoi  BALB/C mice  CL  in vivo  P-4 antigen 
vaccination 
↓lesions 
↑CD8+ and CD4+cells 
↑MIF, IFN-γ and TNF-α 
mRNA in lymph node cells 
Contributes in the control 
of infection in P-4 antigen 
vaccinated mice 
[92] 
        P-4 vaccination 
and CD4+cells 
depletion 
↓parasite 
↓IFN-γ and IL-2 in T cells 
   
      in vitro  Ab anti-MIF 
IFN-γ and 
TNF-α  
↓Leishmanicidal activity in 
Møs from P-4 immunized 
mice 
   
recombinant human MIF (rhMIF); recombinan murine MIF (rmMIF); specific inhibitor of the inducible nitric oxide synthase (L-NIL); = 
cutaneous leishmaniosis (CL); Viceral leishmaniosis (VL); (TCD2) 
 
Trypanosomiasis  
Trypanosomiasis  is  caused  by  protozoan  para-
sites of the genus Trypanosoma. The two major dis-
eases caused by these organisms are sleeping sickness 
in  Africa  and  Chagas  disease  in  America.  Chagas 
disease is a zoonosis (or an anthropozoonosis) caused 
by  the  flagellated  protozoan  parasite  Trypanosoma 
cruzi. It is transmitted to man by the infected feces of a 
blood-sucking  triatomine  bug  through  the  insect 
sting.  An  estimated  18  million  people  are  infected 
worldwide, and most cases occur in Latin America, 
where Chagas disease is endemic. More than 100 mil-
lion people are at risk of contracting the disease [93]. 
Sleeping sickness is a parasitic disease transmitted by 
the bite of the 'Glossina' insect, commonly known as 
the  tsetse  fly.  This  disease  threatens  more  than  55 
million  people  in  36  countries  with  an  estimated 
300,000 new cases per year in Africa alone [94]. 
There are few, but notable, papers regarding the 
role of MIF in trypanosomiasis. Our group has found 
that  infected  (Trypanosoma  cruzi  or  the  Queretaro 
strain) MIF KO mice displayed high levels of blood 
and  tissue  parasitemia,  which  was  associated  with 
severe heart and skeletal muscle immunopathology. 
Inflamed hearts from T. cruzi-infected MIF KO mice 
showed  high  amastigotes  nests  and  expressed  high 
IFN-γ transcripts, but fewer IL-12, p35, IL- 12, p40, 
IL-23 and iNOS transcripts. Further, these mice suc-
cumbed to T. cruzi infection faster than WT mice. This 
enhanced susceptibility in MIF KO mice was associ-
ated  with  an  important  reduction  of 
pro-inflammatory cytokines in the sera during early 
infection. TNF-α, IL-12, IL-18, IFN-γ and IL-1β levels 
correlated with the impaired spleen cell production of 
pro-inflammatory  IL-12  and  IFN-γ,  but  an-
ti-inflammatory IL-4 and IL-10 cytokine levels were 
not  elevated,  demonstrating  that  the  increased  sus-
ceptibility  was  not  due  to  high  production  of  an-
ti-inflammatory  cytokines.  Therefore,  MIF  may  be 
required for the optimal activation of host innate re-
sponses by up-regulating inflammatory cytokines that 
are crucial for resistance to T. cruzi infection [95]. In 
relation to this, a recent study by Nishimura K et al 
reported that MIF, GM-CSF, IL-12 and TNF mRNA 
are highly expressed in spleen macrophages during 
Trypanosoma brucei brucei (ILS) infection, in contrast to 
Trypanosoma gambiense welcome strain (WS) infection, 
the authors explained that this defference may be due 
to a possible macrophage activation during ILS infec-
tion and a macrophage immunosupression during WS 
infection,  probably  by  differences  in  charateristics 
between WS and ILS, these findings indicate that MIF 
is  involved  in  the  inflammatory  immune  response 
against  Trypanosomiasis  and  this  involvement  may 
depend on the parasite strain [96]. Additionally, Paiva 
et al. reported a lethal synergism between T. cruzi in-
fection  and  LPS-induced  shock,  where  MIF  and 
TNF-α play an important role. Briefly, BALB/c mice 
infected with the T. cruzi Y strain after an LPS injec-
tion showed enhanced susceptibility to endotoxemia. 
This  was  in  contrast  to  TNF  KO  mice  treated  with 
anti-MIF,  indicating  that  increased  susceptibility  to 
endotoxemia  is  due  to  T.  cruzi  induced  MIF  and 
TNF-α, suggesting again that MIF may act synergis-
tically  with  the  TNF  pathway  to  induce Int. J. Biol. Sci. 2011, 7 
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pro-inflammatory  responses  during  early  infection 
[97].  Interestingly,  hearts  and  skeletal  muscle  from 
infected mice (RA T. cruzi strain) showed early MIF 
mRNA  induction,  which  was  accompanied  by  en-
hanced  transcripts  for  cytokines,  chemokines  and 
chemokine  receptors,  such  as  TNF-α,  IFN-γ,  CCL5, 
CXCL9, CCR5, CXCR3 and iNOS. These results lead 
to  the  consideration  of  MIF  as  part  of  the  primary 
response against this parasite, and that it acts by col-
laborating with other cytokines and chemokines in the 
inflammation processes of infected organs and tissues 
[98]. In addition, a recent study reported that, in T. 
brucei  infected  C57BL/6  mice,  MIF,  together  with 
important chemokines (CXCL9, 10, CCL2, 3, 4, and 5 
mRNA),  are  significantly  induced  during  the  first, 
and important, peak of parasitemia and the highest 
expansion  of  CD11b+Ly6C+  monocytic  cells  in  the 
liver.  However,  studies  in  MIF  KO  infected  mice 
showed that the egression of CD11b + Ly6C + mono-
cytes  from  the  bone  marrow  to  the  blood  is 
MIF–independent,  but  CCR2-dependent,  indicating 
that  MIF  does  not  participate  in  monocyte  recruit-
ment. However, it may be possible that the early in-
duction  of  MIF  in  the  liver  better  regulates  inflam-
matory cytokine production. Together, these studies 
designate an important role for MIF in the induction 
of a resistant innate immune response to T. cruzi in-
fection. Clinical studies in humans will be necessary 
to confirm these data [99]. 
Table 3. MIF in Trypanosomiosis 
Parasite  Model  Disease   in vitro/ 
in vivo 
Treatment   Properties   MIF role     Ref.  
T. cruzi  
Ninoa 
WT  
MIF-KO 
BALB/c 
mice 
Acute trypano-
somiasis 
in vivo    ↑ parasitemia 
↑Mortality 
Activation of innate im-
munity, inducing in-
flammatory cytokines 
[95] 
 
T. cruzi  
Queretaro 
WT 
MIF-KO 
BALB/c 
mice 
Acute trypano-
somiasis 
in vivo    ↑parasitemia 
↑Mortality 
↓IL-12, IFN-γ, TNF-α, IL-18, IL-1β, 
iNOS mRNA 
↑pathology in heart and skeletal 
muscle 
↓IgG2a Ab 
Activation of innate im-
munity, inducing in-
flammatory cytokines 
[95] 
 
      in vitro  T. cruzi Ag  ↓IL-12 and IFN-γ by spleen cells     
T. brucei 
brucei (ILS) 
Wistar 
Rat 
Trypanosomiasis  In vivo    Unchanged parasitemia and No. of 
spleen Møs compared to 
WS-infected rats. 
 
↑IL-12, ↑TNF, ↑GM-CSF and ↑MIF 
mRNA but ↑IL-10 expression by 
spleen Møs from ILS-infected rats 
(at 4 days p.i.) compared to unin-
fected 
 
↑ Phagocitic activity, ↑IL-12, 
↑TNF↑GM-CSF and ↑MIF mRNA 
but ↓IL-10 expression by spleen 
Møs from infected rats (at 4 days 
p.i.) compared to WS infected rats. 
MIF is highly expressed 
and may participate in the 
immune response to ILS 
infection, in contrast to 
WS infection due to a 
possible Møs immuno-
supression during WS 
infection. 
[96] 
      In vitro  ILS infection  ↑ Phagocitic activity, ↑GM-CSF, 
↑M-CSF and ↑MIF but ↓IL-10 
mRNA expression by ILS infected 
spleen Møs commpared to unin-
fected Møs. Similar results were 
obtained using HS-P cells 
   
        ILS infection  ↑ Phagocitic activity but similar 
GM-CSF, M-CSF and MIF mRNA 
expression by ILS infected spleen 
Møs commpared to WS infected 
Møs. Similar results were obtained 
using HS-P cells 
   
        Cobalt Chlo-
ride 
↑GM-CSF and ↑MIF but ↓M-CSF by 
ILS infected spleen Møs 
commpared to WS infected Møs 
treated with cobalt chloride. Simi-
lar results were obtained using 
HS-P cells. 
   
T. brucei 
gambiese 
welcome 
strain (WS) 
Wistar 
Rat 
Trypanosomiasis  In vivo    ↑M-CSF mRNA expression by 
spleen Møs from WS-infected rats 
(at 4 days p.i.) compared to unin-
fected 
↑IFN-γ, ↑IL-10, ↑M-CSF but ↓ 
   
[96] Int. J. Biol. Sci. 2011, 7 
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Phagocytic activity ↓MIF ↓GM-CSF 
↓IL-12 and ↓TNF mRNA expres-
sion by spleen Møs from infected 
rats (at 4 days p.i.) compared to ILS 
infected rats 
 
↑IL-12, TNF,IFN-γ and IL-10 
mRNA expression by spleen Møs 
from infected rats (at 4 days p.i.) 
compared to uninfected 
      In vitro  WS infection  ↑ M-CSF, ↑GM-CSF and ↑MIF 
mRNA expression by WS infected 
spleen Møs compared to uninfect-
ed Møs. Similar results were ob-
tained using HS-P cells 
 
↓Phagocitic activity but similar 
GM-CSF, M-CSF and MIF mRNA 
expression by WS infected spleen 
Møs commpared to ILS infected 
Møs. Similar results were obtained 
using HS-P cells 
   
        Cobalt chlo-
ride 
↓ GM-CSF and ↓MIF but un-
changed phagocytic activity and 
M-CSF expression by WS infected 
spleen Møs commpared to ILS 
infected Møs treated with cobalt 
chloride. Similar results were ob-
tained using HS-P cells. 
   
T. cruzi 
 Y strain 
BALB/c 
mice 
Acute trypano-
somiosis 
in vivo  LPS  ↑LethalShock ↑Mortality  MIF or TNF-R1 induced 
by T. cruzi are sufficient to 
cause death of infected 
mice upon LPS induced 
shock 
[97] 
T. cruzi  
RA strain 
BALB/c 
mice 
Acute trypano-
somiosis 
in vivo    ↑MIF, TNF-α, IFN-γ CCL5, CXCL9, 
CCR5, CXCLR3 
↑ iNOS in hearts 
↑MIF,TNF-α, CCL5, CXCL9, IFN-γ, 
iNOS, CCR5 and CXCLR3 in skel-
etal muscle 
↑MIF in the primary re-
sponse against the para-
site and it is present in 
association with a state of 
muscle inflammation and 
rhabdomyolysis shortly 
after infection 
[98] 
T. brucei   C57BL/6 
mice 
Acute trypano-
somiosis 
    ↑MIF, CCL2,3,4,5 and CXCL9  MIF don’t participate in 
the recruitment of 
CD11+LY6+ cells 
 
               
IgG2a antibody (IgG2a Ab); CC chemokines ligand (CCL); chemokine receptor (CCR); CX chemokines ligand (CXCL). 
 
Toxoplasmosis  
Toxoplasmosis is an infectious disease caused by 
Toxoplasma  gondii,  an  obligate  intracellular  parasite 
member  of  the  phylum  Aplicomplexa.  Immunocom-
promised patients are commonly affected in the brain, 
as well as other organs, such as the lungs, heart and 
eyes. Moreover, congenital toxoplasmosis is acquired 
if a women contracts a primary infection while preg-
nant [100]. The incidence of congenital toxoplasmosis 
varies between countries. For example, the incidence 
is as high as 10 per 1,000 individuals in France [101] 
but only five per 10,000 in the UK [102] and one per 
10,000 in the USA [103]. Interestingly, approximately 
one-third of the world’s population is seropositive for 
this parasite [104]. 
We found that MIF KO BALB/c mice succumbed 
faster to challenge with virulent (RH) and avirulent 
(ME49) strains of T. gondii compared to WT mice. This 
susceptibility was associated with a high percentage 
of infected peritoneal macrophages, greater numbers 
of cysts in brain, severe liver damage and defective 
early production of proinflammatory cytokines (IL-12, 
IL-1β, TNF-α, IL-18, IFN-γ and nitric oxide). Moreo-
ver, both WT and MIF KO mice showed comparable 
levels of anti-inflammatory cytokines (IL-4 and IL-10) 
in the sera. In contrast, we observed that the lack of 
MIF alters the function of CD11c+ DCs,  which pro-
duce  low  IL-12  and  TNF-α  levels.  Similarly,  low 
transcript  levels  for  IL-12,  IL-1β  and  TNF-α  were 
found in bone marrow dendritic cells (BMDCs) that 
were  stimulated  in  vitro  with  STAg.  Interestingly, 
brain tissue from patients who died of cerebral toxo-
plasmosis showed scarce MIF production compared 
to patients who died of an encephalitic cryptococcal 
infection. Thus, MIF appears to play a critical role in 
promoting resistance to toxoplasmosis by regulating 
the early production of innate pro-inflammatory cy-
tokines.  Additionally,  lower  expression  of  TNF-αR, 
IFN-γR and TLR-4 was found in PECs from infected Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
1249 
MIF  KO  mice,  suggesting  that  the  absence  of  MIF 
renders cells unable to respond rapidly to T. gondii. 
This is supported by the defective recognition of both 
proinflammatory  cytokines  and  the  parasite  in  MIF 
KO  mice.  These  results  are  consistent  with  a  later 
study in orally infected MIF KO mice [105], demon-
strating  that  the  increased  mortality  in  T. gondii  in-
fected (ME49 strain) MIF KO mice is due to uncon-
trolled parasite replication and dissemination in brain 
and liver. This phenomenon was associated with low 
expression of MHC-II and co-stimulatory molecules 
(CD40,  CD80  and  CD86)  in  mononuclear  lymphoid 
nude (MLN) and splenic DCs during the early infec-
tion.  In  addition,  low  IL-12  production  by  MIF  KO 
DCs was measured compared to DCs from similarly 
infected  or  STAg  intravenous-injected  WT  mice. 
Moreover, MIF KO BMDCs stimulated  in vitro with 
STAg or LPS showed lower expression of the parasite 
recognition  receptor  TLR11,  proinflammatory  cyto-
kines (IL-12, TNF-α, IL-1β) and nitric oxide. Interest-
ingly,  these  expression  deficiencies  were  restored 
upon the addition of exogenous rMIF, indicating that 
interaction with MIF during oral T. gondii infection is 
required  for  DC  maturation  and  the  induction  of  a 
proinflammatory protective immune response. Addi-
tionally,  a  recent  study  has  demonstrated  that  MIF 
production by chorionic villous explants from human 
placentas is upregulated when stimulated with STAg, 
particularly in the villous trophoblast. Upon release, 
MIF  induces  the  dose-dependent  expression  of 
ICAM-1, primarily in the syncytiotrophoblast, leading 
to the adhesion of monocytes (THP-1) on the surface 
of villous explants. This demonstrates that MIF plays 
an essential role as an autocrine/paracrine mediator 
in T. gondii placental infection [51]. Related to this, de 
Oliveira  Gomes,  A.,  et  al,  reported  that  MIF  is 
upregulated by first-trimester placental explants and 
is  important  to  control  T. gondii  infection  due  to  a 
decreased  parasite  load  at  this  gestational  stage,  in 
contrast  to  third  trimester  placental  explants  which 
showed  increased  susceptibility  to  infection, 
suggesting that variations in MIF regulation during 
gestation  have  an  important  role  in  differential 
susceptibility to T. gondii infection [106]. These find-
ings evidence the pleiotropic role for MIF, including 
the maturation of important antigen presenting cells, 
like  DCs,  the  expression  of  parasite  recognition  re-
ceptors,  the  expression  of  adhesion  molecules,  like 
ICAM-1,  and  inducing  pro-inflammatory  cytokines. 
Together, these activities are crucial for the develop-
ment  of  a  protective  innate  immune  response  to  T. 
gondii infection. 
 
Table 4. MIF in Toxoplasmosis 
Parasite  Model  Disease   in vitro/ 
in vivo 
Treatment   Properties   MIF role     Ref.  
T. gondii 
RH  
ME49 
strains 
BALB/c 
MIF-KO 
Acute 
Toxoplas-mosis 
in vivo    ↑Mortality compared to MIF +/+ 
↓IL-12, IL-1β, TNF-α, IL-18 and 
IFN-γ in sera 
↓CCR5 in PECs 
↑Mortality 
↑Parasited Mø 
↑Cystis in brain 
↑ALT and AST (Liver damage) 
TNF-αR PECS 
↓ IFN-γR in splenocytes 
 ↓IL-12 and TNF-α on CD11c+ LOD 
DCs. 
 
Promotes resistance 
inducing early pro-
duction of 
pro-inflammatory 
cytokines, and 
TLR11expression  
 
[121] 
      in vitro  STAg or LPS  IL-12p35, IL-12p40, IL-12p19, IL-1β 
and TNF-α in BMDCs 
   
T. gondii 
RH strain 
C57BL/6    in vivo    ↓MIF in sera  
 
 
   
T. gondii  Human 
 
  in vivo 
 
 
 
 
↓MIF in brains from patients who 
died by encephalitic 
   
T. gondii 
ME49 strain 
Murine 
BALB/c 
MIF-KO 
Acute 
Toxoplasm-osis 
in vivo    ↑Mortality 
↑Brain cysts  
↑Parasitemia and ↓Inflammation 
infiltrates in liver during early infec-
tion. 
↓MHCII, CD80, CD86 and CD40 
expression in MLN DCs and splenic 
DCs. 
 ↓ MLN DCs producing IL-12 
Modulates the innate 
immunity to T. gondii 
oral infection by regu-
lating maturation and 
cytokine production of 
DCs 
[105] 
      in vivo  STAg via 
intravenous 
↓IL-12 in sera 
↓IL-12 by splenocytes. 
↓ IL-12 by splenic DCs 
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      in vitro  STAg or LPS  ↓MHCII, CD86, CD80, CD40 and 
TLR11 expression in BMDCs 
   
        STAg or LPS  ↓Allostimulatory ability of DCs (low 
CD4+ proliferation) 
   
        MIF+ STAg or 
LPS 
 ↑IL-12, TNF-α, IL-1β, ON and 
TLR11expression in BMDCs com-
pared to STAg or LPS treatments 
   
T. gondii RH 
strain 
Human  Experimental 
placental toxo-
plasm-osis 
Ex vivo  STAg  ↑MIF by CVE 
↑Intracellular MIF in CVE 
↑MIF in the Syncytiotrophoblast of 
CVE 
Induces the ICAM-1 
and adhesion of mon-
ocytes cells which may 
be an important 
mechanism for con-
trolling T. gondii infec-
tion in the placental  
 
         SPN or  
rMIF 
↑ICAM-1 in the syncytiotrophoblast 
of CVE. 
   
        SPN + an-
ti-MIF anti-
bodies 
↓ ICAM-1 in the syncytiotrophoblast 
of CVE. 
   
        SPN or  
SPN+ an-
ti-MIF or rMIF 
↑Monocyte (THP-1) adhesion in the 
trophoblast of explants cultures 
   
               
T. gondii RH  Human  Toxoplasm-osis  In vitro    ↑CD74R in syncytiotrophoblast and 
mesenchymal cells from uninfected 
first-trimester placental explants 
(FTPE) compared to Third-trimester 
placental explants (TTPE) 
MIF is up-regulated in 
first-trimester explants 
in contrast to 
third-trimester pla-
cental explants and is 
important to control T. 
gondii infection. 
[106] 
          ↑MIF expression in cytotrophoblast 
layer by uninfected FTPE compared 
to TTPE 
   
        IFN-γ or IL-12  ↑MIF release by uninfected FTPE 
compared to untreated  
   
         IL-10 or 
TGF-β  
Un changed MIF discharge by unin-
fected FTPE  
   
          ↑MIF release by infected FTPE com-
pared to uninfected or infected TTPE 
   
          ↑↑MIF release by infected FTPE      
         IL-10 and 
TGF-β  
↑MIF release by infected FTPE      
          ↑MIF expression in the Syncytio-
trophoblast layer and mesenchyme 
from infected FTPE  
   
        rMIF  ↓Parasite load in FTPE      
        IL-12  ↓Parasite load in FTPE      
        IFN-γ  ↓Parasite load in FTPE      
        IFN-γ  ↑MIF release by infected TTPE     
          ↑MIF expression in cytotrophoblast 
layer from infected TTPE 
   
 
Chorionic Villous explants (CVE); recombinant MIF (rMIF); Soluble Toxoplasma Antigen (STAg); Supernatants from explants cultures ex-
posed to STAg (SNP). 
 
Primary Amebic Meningoencephalitis  
The  genus  Naegleria  consists  of  a  group  of 
free-living  ameboflagellates  (FLA)  found  in  diverse 
habitats  throughout  the  world,  such  as  freshwater 
lakes,  ponds,  domestic  water  supplies,  swimming 
pools and thermal pools [107-109]. Although over 30 
species of Naegleria have been isolated from environ-
mental sources, only Naegleria fowleri has been isolated 
from humans. N. fowleri causes primary amebic me-
ningoencephalitis (PAM). PAM is a rapidly fatal dis-
ease affecting the central nervous system (CNS) that 
occurs most often in immune-competent individuals, 
such as children and young adults with a history of 
swimming and diving in freshwater [110]. 
Little  is  known  about  the  role  of  MIF  during 
amoebic parasite infection; however, a pioneer study 
by Cursons et al. reported that lymphocytes  stimu-
lated with N. fowleri, N. jadini and N. gruberi antigens 
released MIF, which inhibited the migration of peri-Int. J. Biol. Sci. 2011, 7 
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toneal exudate cells. Moreover, guinea pigs sensitized 
to  the  three  species  of  Naegleria  developed  typical 
delayed type hypersensitivity (DTH) reactions when 
inoculated intradermally with amoeba antigens [111]. 
In addition Haq, A. et al, showed that Peritoneal cells 
from  hamsters  sensitized  with  Entamoeba  histolytica 
antigens  (EHA)  produced  high  MIF  levels  when 
stimulated in vitro with amoeba antigens, moreover 
the  production  of  MIF  was  found  to  be  greatly  in-
creased  in  animals  sensitizing  by  EAH  plus  glucan 
[112]. MIF may be participating in the resistance to 
PAM and amebiasis; however, this is merely the be-
ginning of a series of studies that aim to reveal the role 
of  MIF,  and  may  be  helpful  in  the  development  of 
therapeutic treatments for this disease. 
 
Table 5. MIF in Amebiosis 
Parasite  Model  Disease   in vitro 
 in vivo 
Treatment   Properties   MIF role     Ref.  
Naegleria 
flowleri 
Naegleria 
jadini 
Guinea pigs  PMA  in vivo  Naegleria Ag 
+ Freund  
adjuvant 
↑Infiltration of mononuclear 
cells in lesions  
Favors the resistance to 
infection(MIF is involved 
in the immune response 
against PMA) 
 
[111] 
Naegleria 
gruberi 
    in vitro 
 
  ↑ MIF supernatants of Lym-
phocytes stimulated with 
Naegleria Ag 
   
Entamoeba 
histolytica 
Hamsters  Amoebiasis  In vitro  Entamoeba 
histolytica 
antigens 
↑ MIF in supernatants of Peri-
toneal cells from E. histolyti-
ca-sensitized hamsters 
Favors the resistance to 
infection (MIF is involved 
in the immune response 
against amebiasis) 
[112] 
        Entamoeba 
histolytica 
antigens + 
glucan 
↑↑ MIF in supernatants of Peri-
toneal cells from E. histolyti-
ca-sensitized hamsters 
   
Primary Amebic Meningoencephalitis (PMA) 
 
Neosporosis  
MIF  has  achieved  great  relevance  for  groups 
aiming to study the immune response against intra-
cellular parasite infection. Recently, it has been stud-
ied in neosporosis [113], an infectious disease caused 
by  Neospora  caninum,  an  obligate  intracellular 
apicomplexa parasite, closely related to T.gondii [114]. 
Neosporosis is recognized as a major cause of spon-
taneous abortion in cattle worldwide [114], and it has 
been proposed that humans are probable hosts for this 
parasite [115, 116].  
Carvalho  et  al.  found  that  after  an  in  vitro 
Neospora  caninum  infection,  both  human  uterine 
cervical  HeLa  and  choriocarcinoma  BeWo  cells 
expressed  high  MIF  levels.  In  this  study,  although 
BeWo  cells  expressed  lower  MIF  levels  than  HeLa 
cells, BeWo cells presented a lower index of infection, 
decreased  cell  lysis,  reduced  parasite  replication, 
more  viability  and  higher  TGF-β  levels  than  HeLa 
cells.  Aditionally,  pretreatment  with  IFN-γ  reduced 
infected in BeWo cells, parasite replication in HeLa 
cells, TGF-β levels in BeWo cells and increased MIF 
levels in both cell types. Using IDO-specific inhibitors 
(1-MT), IFN-γ-mediated inhibition of parasite growth 
in  HeLa  cells  was  demostrated  to  be  IDO  enzyme 
dependent. Moreover, pretreatment with N. caninum 
lysate  antigen  (NLA)  increased  MIF  levels  in  HeLa 
cells, but decreased TGF-β production in BeWo cells 
[113]. Given the increased MIF production by both cell 
types  in  response  to  IFN-γ  and  that  N.  caninum 
infection  and  NLA  administration  correlates  with  a 
low  infection  index  and  parasite  replication,  these 
results suggest that MIF may play also a role in the 
inmune response against N. caninum infection in the 
placenta. 
Coccidiosis  
Avian  coccidiosis  is  an  intestinal  infection 
caused  by  apicomplexan  protozoa  belonging  to  at 
least seven different species of Eimeria [117]. In nature, 
eimerian  infections  occur  when  hosts  ingest  sporu-
lated oocysts, resulting in a mild or severe disease, 
characterized  by  anorexia,  digestive  disturbances, 
dehydration, blood loss, and increased susceptibility 
to  other  disease  agents  [118].  Coccidiosis  is  an  im-
portant disease economically due to morbidity, mor-
tality  and  reduced  production  efficiency  of  poultry 
and other livestock. It is estimated to be responsible 
for monetary losses greater than $3 billion annually 
[119]. 
Previous studies regarding the pleiotropic role of 
MIF have revealed its potential use as a therapeutic 
agent  for  a  variety  of  human  parasite  infections; 
however, its role in domestic animals like poultry has 
only recently been investigated. Interestingly Hong et Int. J. Biol. Sci. 2011, 7 
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al.  found  increased  transcripts  for  MIF  and  other 
chemokines  (MIP-1β,  K203,  IL-8  and  limphotactin), 
pro-inflammatory cytokines (IFN-γ, IL-1β, IL-6, IL-12, 
IL-15  and  IL-17)  and  anti-inflammatory  cytokines 
(IL-3, IL-4, IL-10, IL-13 and GM-CSF) in intraepithelial 
lymphocytes  (IELs)  from  the  intestinal  jejunum  of 
chickens  during  experimental  Eimeria maxima  infec-
tion. In addition, the authors reported high expression 
of the surface markers K1, CD3, CD4, CD8, TCR1 and 
TCR2 from different IELs subpopulations [120], which 
were similar to those found in experimental Eimeria 
acervulina and Eimeria tenella infections from an addi-
tional study [117]. Therefore, MIF, together with other 
chemokines, cytokines and IEL subpopulations, me-
diates host defense mechanisms against Eimeria infec-
tion. However, the role of MIF as a chemokine or a 
potent  inducer  of  proinflammatory  cytokines  will 
need further clarification.  
Concluding remarks 
Since the discovery of MIF, we have witnessed 
slow  progress  in  our  understanding  of  the 
MIF-mediated  immune  mechanisms  in  infectious 
diseases, such as the protozoan parasites that cause 
major  human  diseases  in  the  developing  world,  in-
cluding  malaria,  human  African  trypanosomiasis, 
Chagas  disease,  leishmaniasis  and  toxoplasmosis. 
Although the life cycles of these parasites were de-
fined  years  ago,  specific  therapeutic  or  preventive 
interventions are not yet available, and better under-
standing of the immune response to these protozoans 
is required. Recently, MIF has been considered a key 
player in protozoan infections, where it plays a piv-
otal role in early innate immunity rather than favoring 
the  adaptive  immune  response.  However,  the  role 
MIF plays in the response to protozoan infection is 
complex.  For  example,  high  levels  of  MIF  can  be 
dangerous for the host during malaria infections (Fig 
2), on the other hand, MIF appears to be necessary to 
successfully  control  leishmaniasis,  trypanosomiasis, 
toxoplasmosis,  neosporosis,  coccidiosis  and  menin-
goencephalitis (Fig 3). Together, the studies described 
in this review suggest that MIF participates in regu-
lating the expression of some important molecules of 
the early immune response to different protozoa in-
fections.  However,  the  exact  mechanism  by  which 
MIF acts during the immune response against para-
sites  has  not  yet  been  defined.  MIF  signaling  path-
ways have not been demonstrated for the activation of 
innate immunity during protozoa infections. Under-
standing the complex nature of these innate immunity 
responses  will be necessary for the development of 
strategies to target MIF therapeutically, or for the de-
velopment  of  a  novel  adjuvant  or  vaccine  against 
protozoan infections.  
 
 
Figure 3. Overview of MIF in Protozoan infections. Infected mice with intracellular protozoan (exception plasmodium) 
parasites (1) have high levels of MIF in serum (3) produced mainly by the immune cells (2). MIF acts in paracrine and au-
tocrine manner (4) favoring the expression of proinflammatory cytokines and its receptors, chemokines, parasites recog-
nition receptors and costimulatory molecules on antigen presenting cells (5). These conditions favor the microbicidal activity 
by macrophages, cellular chemiotaxis, parasite recognition and efficient antigen presentation (6). All together indicate that 
MIF has a protective role against protozoan infections (7). Int. J. Biol. Sci. 2011, 7 
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